Home

Barbara W. Bodem

CIK 1713893 · SVP, Chief Financial Officer · last filed 2026-06-04

Barbara W. Bodem is a SVP, Chief Financial Officer who has filed 33 SEC Form 4 insider transactions across 7 companies since 2017. The most recent filing, for BMRN, was dated Jun 4, 2026. Current disclosed insider exposure totals $2.3M across reported positions. 13 SEC filings were submitted jointly with HILLENBRAND INDUSTRIES INC.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$2.34M

Companies

7

Total Filings

33

Lifetime Open-Market Net

$0

Filer Profile

Reported Address
C/O BIOMARIN PHARMACEUTICAL INC.
105 DIGITAL DRIVE
NOVATO, CA 94949
Related Filers
HILLENBRAND INDUSTRIES INC — 13 joint filings, latest 2021-12-15
Enovis CORP — 6 joint filings, latest 2026-05-21
BIOMARIN PHARMACEUTICAL INC — 5 joint filings, latest 2026-06-04
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
BMRN Director 21,045 $65.68 $1.38M $0 4 2026-06-04
OPCH Director 21,087 $23.48 $495.1K $0 4 2026-05-22
ENOV Director 24,201 $19.28 $466.6K $0 5 2026-05-21
Syneos Health, Inc. (SYNH) Delisted Director 0 $42.98 $0 $0 4 2023-09-28
Turning Point Therapeutics, Inc. (TPTX) Delisted Director — $76.01 — $0 2 2022-08-17
Hill-Rom Holdings, Inc. (HRC) Delisted SVP, Chief Financial Officer 14,591 $155.96 $2.28M $0 11 2021-12-08
INVACARE HOLDINGS Corp (IVC) Delisted Director 11,728 $0.66 $7.7K $0 2 2018-03-20

Recent Filings

33 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-06-04 BMRN Grant (A) +7,490 $0 EDGAR
2026-05-22 OPCH Grant (A) +8,997 $0 EDGAR
2026-05-21 ENOV Grant (A) +9,346 $0 EDGAR
2025-05-23 ENOV Grant (A) +6,598 $0 EDGAR
2025-05-22 BMRN Grant (A) +6,650 $0 EDGAR
2025-05-19 OPCH Grant (A) +5,034 $0 EDGAR
2024-05-23 BMRN Grant (A) +4,720 $0 EDGAR
2024-05-22 ENOV Grant (A) +4,338 $0 EDGAR
2024-05-17 OPCH Grant (A) +5,325 $0 EDGAR
2024-04-03 OPCH Grant (A) +1,731 $0 EDGAR
Showing 1–10 of 33
Page 1 of 4
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.